470 related articles for article (PubMed ID: 25282185)
1. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
2. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
[TBL] [Abstract][Full Text] [Related]
3. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Yamasaki Y
Diab Vasc Dis Res; 2008 Sep; 5(3):190-7. PubMed ID: 18777492
[TBL] [Abstract][Full Text] [Related]
4. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study.
Heier M; Margeirsdottir HD; Gaarder M; Stensæth KH; Brunborg C; Torjesen PA; Seljeflot I; Hanssen KF; Dahl-Jørgensen K
Cardiovasc Diabetol; 2015 Sep; 14():126. PubMed ID: 26408307
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.
Kim JK; Park S; Lee MJ; Song YR; Han SH; Kim SG; Kang SW; Choi KH; Kim HJ; Yoo TH
Atherosclerosis; 2012 Jan; 220(1):208-14. PubMed ID: 21906738
[TBL] [Abstract][Full Text] [Related]
6. Low Endogenous Secretory Receptor for Advanced Glycation End-Products Levels Are Associated With Inflammation and Carotid Atherosclerosis in Prediabetes.
Di Pino A; Urbano F; Zagami RM; Filippello A; Di Mauro S; Piro S; Purrello F; Rabuazzo AM
J Clin Endocrinol Metab; 2016 Apr; 101(4):1701-9. PubMed ID: 26885882
[TBL] [Abstract][Full Text] [Related]
7. Association Between Soluble Receptor for Advanced Glycation End Product and Endogenous Secretory Soluble Receptor for Advanced Glycation End Product Levels and Carotid Atherosclerosis in Diabetes: A Systematic Review and Meta-Analysis.
Wang X; Wang Q; Wei D; Chang X
Can J Diabetes; 2021 Oct; 45(7):634-640. PubMed ID: 33773934
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
9. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A
Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256
[TBL] [Abstract][Full Text] [Related]
10. Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.
Loomis SJ; Chen Y; Sacks DB; Christenson ES; Christenson RH; Rebholz CM; Selvin E
Clin Chem; 2017 May; 63(5):980-989. PubMed ID: 28280052
[TBL] [Abstract][Full Text] [Related]
11. High Plasma sRAGE (Soluble Receptor for Advanced Glycation End Products) Is Associated With Slower Carotid Intima-Media Thickness Progression and Lower Risk for First-Time Coronary Events and Mortality.
Grauen Larsen H; Marinkovic G; Nilsson PM; Nilsson J; Engström G; Melander O; Orho-Melander M; Schiopu A
Arterioscler Thromb Vasc Biol; 2019 May; 39(5):925-933. PubMed ID: 30917679
[TBL] [Abstract][Full Text] [Related]
12. High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis.
Basta G; Castagnini M; Del Turco S; Epistolato MC; Righini P; Sangiorgi GM; De Caterina R; Tanganelli P
Eur J Clin Invest; 2009 Dec; 39(12):1065-72. PubMed ID: 19811526
[TBL] [Abstract][Full Text] [Related]
13. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
Prasad K; Dhar I; Zhou Q; Elmoselhi H; Shoker M; Shoker A
Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
[TBL] [Abstract][Full Text] [Related]
14. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis.
Koyama H; Shoji T; Yokoyama H; Motoyama K; Mori K; Fukumoto S; Emoto M; Shoji T; Tamei H; Matsuki H; Sakurai S; Yamamoto Y; Yonekura H; Watanabe T; Yamamoto H; Nishizawa Y
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2587-93. PubMed ID: 16224056
[TBL] [Abstract][Full Text] [Related]
15. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
16. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.
Romero R; Espinoza J; Hassan S; Gotsch F; Kusanovic JP; Avila C; Erez O; Edwin S; Schmidt AM
J Perinat Med; 2008; 36(5):388-98. PubMed ID: 18593373
[TBL] [Abstract][Full Text] [Related]
17. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography.
Yang SJ; Kim S; Hwang SY; Kim TN; Choi HY; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
Atherosclerosis; 2012 Feb; 220(2):402-6. PubMed ID: 22137663
[TBL] [Abstract][Full Text] [Related]
18. Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs.
Abdulle A; Inman CK; Saleh A; Noshi M; Galani D; Abdelwareth L; Alsafar H; Elfatih A; Al Shamsi H; Ali R; Li H; Ramasamy R; Schmidt AM; Benbarka MM; Hassan MH
J Clin Transl Endocrinol; 2019 Jun; 16():100192. PubMed ID: 31080742
[TBL] [Abstract][Full Text] [Related]
19. Assessment of EN-RAGE, sRAGE, and its isoforms: cRAGE, esRAGE in obese patients treated by moderate caloric restriction combined with physical activity conducted in hospital condition.
Kanikowska D; Kanikowska A; Strojny Z; Kawka E; Zawada A; Rutkowski R; Litwinowicz M; Sato M; Grzymisławski M; Bręborowicz A; Witowski J; Korybalska K
Cytokine; 2024 Aug; 180():156665. PubMed ID: 38823153
[TBL] [Abstract][Full Text] [Related]
20. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.
Prasad K
Int J Angiol; 2014 Mar; 23(1):11-6. PubMed ID: 24627612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
